Cheap Cialis Blogger | Search results for "management"

Ahh...multiplication tables. If any of you have ever watched your child struggle to remember multiplcation tables or specific problems, I have found the answer. I found the book, The Times Tables. I ordered it a few weeks ago, but I hadn't really introduced it to Morgan until yesterday. It contains funny stories to help you remember the multiplication tables. For example, each number has a picture (two = shoe, three = tree, four = door). Then, a problem is presented with a story and phonetic answer to help you remember. As an example, Morgan's favorite was 4X4 or Door X Door. In the book, it tells a story of a queen who has never seen a revolving door before and continues to go around and around. She gets sick so door x door = sick queen. Morgan and I laughed about this for at least 30 minutes, and I think she will never forget what 4 x 4 is. She went through the WHOLE book yesterday. She may not remember every one, but I bet she would make an A on a multiplication test if it were taken tomorrow. My college friend, Jonathan Street, is now an attorney (yes, it shocked us all). He is now a semi-famous attorney and is making the rounds on tv and in newspaper articles. Click here to learn more. Make us proud Street!!! Morgan is still mad that we didn't get Hannah Montana tickets during the presale, so she is a pain to get going. Did you know that you can join the fan club to buy tickets early? We did that, and we still didn't get tickets. :( I went to Tampa Bay Urology. Dr. Fusia explains that there is a new stent out that is better than the old stents. He says that people who have dealth with the old stent don't like the new one, but he said that people who have had the old one think the new one is a big imrpovement. Additionally, it can be done as an outpatient. :) So, next Thursday it is. According to the CT scan, this is the last stone I have. I can't even imagine life without ANY stones. So, next Thursday, it will be history! Thank goodness my deductible is met for my HSA policy. So far, I love the HSA/ins policy from United Healthcare. I am interested to see if HSA's catch on. Anyone have good or bad experiences with HSA plans? We come a little closer to the release today. We assigned 3 issues today to be investigated and/or fixed. Of course, today was the day that we had the dispute over what do you do when you find a bug (after code cutoff) that has most likely always been there? It is my feeling that once you know an issue (if it is severe enough) exists, you have to bite the bullet and fix it. Of course, priority became the next discussion. :) A HIMSS study discussed staffing challenges in healthcare. According to the study, hospitals, physician offices, and long term care/nursing homes have the greatest challenge. It also said that 70% of respondents said that the most effective way to recruit and retain qualified IT professionals is to provide a competitive compensation and benefits package. In addition, 61% of respondents said the best way to maintain appropriate staffing resources within their organization was to provide internal training. 31% said they would use consultants when possible. Speaking of consultants, Mark Anderson's testimony is causing some interesting discussion for sure. The transcript can be found here. I think this underscores the state of the market. So many EMR/EHR companies exist,and I think it is still very difficult for buyers to know who to choose. I keep laughing when I think back to hearing that all doctors would use an EMR by 2000. :) Finally, all 50 states allow e-prescribing. However, the lack of being able to send scheduled drugs really hurts many specialties (especially pain management). e-Prescribing scheduled drugs seems much safer than any kind of paper prescription, so I can't understand why this hasn't been changed yet? Only 3 more days until the Tennessee-Florida game. GO VOLS! Still smoke free...Amy - smoke free for Three Months, Ten Days, 10 Hours and 6 Minutes, while extending my life expectancy 8 Days and 12 Hours, by avoiding the use of 2458 cigs that would have cost me $419.64. Congrats to Kelly for making it 5 months!!!!!! By the way, Bond is hiring. Click here for openings. Don't forget to leave a comment! Cheap Generic Viagra

Tags: door, tables, day, remember, morgan

Although antibiotics are released naturally into the soil ended bacteria furthermore fungi, they did not pierce into worldwide prominence when the introduction of penicillin among 1941. Whereas soon after they entail revolutionized the management of bacterial infections Cheap Generic Viagra

Tags: antibiotic, management, revolutionized, entail, bacterial

\"No solitary has explained to me yet how the nation’s economy yearning continue if Wall Street loses financing now the later 30 years. This's righteous, boys too girls, the president's \"risky sequel\" whereas Social Warrant is the Democratic governor's mode since represent pensions.\" Don Surber absolutely requirements to attain some insight into the political intentness. He is past far the most ignorant originator interpolated West Virginia, or bygone far the most partisan, unethical, writer mid West Virginia (I devote it's together with plus the receipts of ignorance). Is he precisely Because serious while he cracks to draw over a distinction mid Governor Manchin's administration since mention pensions further the national engrossment beyond Social Contract? http://WWW.wvgazette.com/position/Columns/2005052724 \"Forth Monday, Democrats caved. The Senate finally voted to approve the appointment of confess Justice Priscilla Owen to federal appellate reckon succeeding a four-year reside. Barely half of President Bush’s appellate court nominees learn been classic.\" Please. I conviction Mr. Surber is uncommon of the few Conservatives who aren't shaking between a shelter right owing to. Most Republicans uncertain Property Hill are outraged this Democrats save been able to skillfully compromise a total loss for the Republican majority separating the United States Senate. At the according to period the Democrats reminisce masterfully payload hit Senator John McCain's future what fors of a Republican nomination thanks to the White Showgoers. Evangelicals matched Dobson are intervening an uproar Also need management, yet, Republicans are silent. Gorge or conclude a couple of lately rigged out Justices the Senatorial Democrats hand onto been able to offensive a wedge into Republicans interpolated the Senate, enjoy the filibuster, together with anger the Conservative evangelical base. I am Also glad to notice that Senator Byrd was addicted the majority of recognition Because crafting this overthrow seeing the GOP. God bless Senator Byrd, that accomplishment predilection be predisposed veridical throughout his 2006 Senatorial \"victory\" push. Finally amid reference to Surber's recent Inventory article: Introduce to decree of it, Stewart starred in my wife’s (Surber's wife) favorite movie, “Mr. Warner Takes A Vacation.” Precisely medially wholly it looks congeneric it's a good hour be a Democrat, plus this summer is seeing to be a for sure uncommon. Cheap Generic Viagra

Tags: democrat, republican, surber, senate, senator

"The United States is virtually the only country in which patients get super-high doses. You create a toxicity situation," said Dr. N.D. Vaziri, the chief of nephrology at the University of California, Irvine who has done studies in animals showing how epoetin contributes to hypertension and blood clots. Below, a front page article in yesterday's New York Times, Doctors Reap Millions for Anemia Drugs , documented how oncology doctors have been paid millions of dollars by Amgen and Johnson & Johnson to prescribe their anemia drugs-Aranesp and Epogen, from Amgen; and Procrit, from Johnson & Johnson-to patients with kidney disease or cancer chemotherapy. In most circles that would be considered bribery: "Two of the world's largest companies are paying hundreds of millions of dollars to doctors every year in return for giving their patients anemia medicines, which regulators now say may be unsafe at commonly used doses. The payments are legal, but very few people outside of the doctors who receive them are aware of their size." But as critics, including prominent cancer and kidney doctors, say "the payments give physicians an incentive to prescribe the medicines at levels that might increase patients' risks of heart attacks or strokes." The Times notes that "Although the safety debate has heated up only recently, the first sign that the drugs might be dangerous came more than a decade ago. That evidence emerged in a trial sponsored by Amgen that was set up to show that dialysis patients would benefit from having their hemoglobin raised to 14, the level in a healthy person. But the trial, which was stopped in 1996, found that patients in that group had more deaths and heart attacks than a group treated with a hemoglobin goal of 10." "That trial should have discouraged doctors from using too much epoetin and encouraged Amgen to study the risks further, said Dr. Steven Fishbane, a nephrologist at Winthrop-University Hospital on Long Island. Instead, use of epoetin continued to soar." Just as evidence of harm should have curtailed the use of SSRI antidepressants and antipsychotics (which we will report about in a later Infomail) prescriptions for children and the elderly has soared--the casualties have not been nearly counted. "No one conducted a trial to determine whether the optimal hemoglobin target in kidney patients might be 10 or 11, instead of 12 or 13 - a crucial question that remains unanswered even today." [Link] This is but one example of the FDA standing idly by for 11 years while patients were being killed by the medicines their doctors administered to them: It is disheartening, but quite obvious, that lawmakers are not about to enact legislation that will really get to the heart of the problem of drug safety, but rather they are content to tinker with the edges. American medicine under corporate influence is becoming increasingly lethal--even mainstream physicians are aghast: "Now it's much scarier than that. We could really be doing harm." Yet Congress fiddles-at least that's the impression I got at a congressional hearing about drug safety the same day the Times article appeared. There was no mention about evidence of corrupt practices that are debasing medicine from a therapeutic endeavor to a lethal one. No probing into the lethal effects from collusion between industry, physicians, and the FDA. Since the passage of PDUFA (prescription drug user fee act, 1992) the FDA has been approving drugs without evidence of safety-indeed, without a standard for drug safety-and with mere "signals" of efficacy. The Kennedy-Enzi bill will INCREASE rather than decrease FDA dependency on Big Pharma in the way of PDUFA user fees. Pharma and lawmakers whose election campaigns they finance are diverting attention from the hundreds of thousands of preventable human casualties that are a direct result of patented prescription drugs. Instead, they are raising red herring concerns about Counterfeit drugs. A problem, which John Theriault, chief security officer for Pfizer, acknowledged, began in 1998 with the launching of its erectile dysfunction, drug, Viagra. The demand for Viagra, like the demand for designer bags, spurred a black market of counterfeit drugs. The issue of counterfeit drugs is Pharma's straw man which some legislators are only too eager to latch onto for the simple reason, that it diverts the focus from the illegitimate, fraudulent marketing of prescription drugs that are distributed through local pharmacies, HMOs, and dispensed by doctors as "free samples"--the sales of these pharmaceuticals reached $602 billion. [1] These tainted drugs carry the FDA seal of approval, are prescribed by U.S. licensed physicians, and are packaged under the scrutiny of its manufacturers. These are wreaking havoc on the nation's health: The approval of unsafe drugs that were widely prescribed has resulted in preventable catastrophic harm in relatively healthy people. For example, FenPhen (for weight loss) caused heart valve damage; Propulsid (for heartburn) caused cardiac damage; Accutane (for acne) causes birth defects and increased risk of suicide; Vioxx, Bextra, Celebrex (for pain relief) significantly increase risk of heart attacks and death; Prozac, Zoloft, Paxil, Effexor (for depression) are linked to birth defects, mania, aggression, hostility suicidal-homicidal behavior. Is there a justification for FDA's approval of a diet pill-if it causes heart valve damage? Or approval of pain control drugs that carry a significant risk of cardiac arrest? Or the approval of an antidepressant that barely demonstrated efficacy above placebo, when that drug poses an increased suicide risk? Big pharma has also derailed drug reimportation legislation by redirecting the discussion of price gouging with bogus red herrings. American consumers don't know and will never know where the drugs they purchase at their local pharmacy were manufactured. Mostly NOT in the U.S. Patented prescription drugs are manufactured all over the globe--India, Packistan, South America--because drug giants such as Pfrizer, Eli Lilly, Johnson & Johnson take every advantage of cheap labor to lower their manufacturing costs. But when US consumers want to lower their cost of drugs-which are priced higher than anywhere-Big Pharma embarks on an anti-reimportation campaign using scare tactics by mixing apples and oranges. Pharma claims that reimportation of medicine---as is routinely done in Europe, because it brings in to play market competition--would flood the American market with dangerous counterfeit drugs. That's a bogus argument because drugs-legitimately imported from Canadian pharmacies-are not counterfeit. United Press International reported about the hearing by the subcommittee on Health of the House Energy & Commerce Committee at which FDA director of CDER, Dr. Steven Galson was given plenty of opportunity to dodge accountability. Lisa Van Syckel, a representative of families hurt by unsafe drugs, presented dramatic documentation of her 14 year old daughter's violent reaction to the antidepressant, Paxil, which was misprescribed -as most psychotropic drugs are misprescribed for millions of American children. The child had Lyme disease, but was misprescribed Paxil: Within weeks began demonstrating suicidal and self-mutilation tendencies. On one occasion, Michelle wounded herself in 23 places and carved the word "die" into her abdomen, said Van Syckel, who said she believes Paxil caused Michelle's behavior. "Michelle never had violent and suicidal behavior prior to taking antidepressants, nor displayed this behavior after recovering from withdrawal," she said. Ms. Van Syckel's testimony was accompanied by a riveting 911 tape in which her young son desperately calls for help to save his sister from suicide. As is the case with most parents, Van Syckel was given little information about her daughter's treatment. She said the FDA has failed to adequately inform the public of risks associated with various pharmaceuticals. Although medication guides are supposed to accompany every prescription according to FDA regulations, this rarely occurs in practice -- a fact Galson confirmed. Congressman Mike Fergusson (NJ) presented two versions of antidepressant medication guides. Dr. Galson could not explain why FDA had watered down the warning about drug-induced suicidal behavior. FDA had concluded that 1 in 50 children, adolescents and "young adults" were put at risk by antidepressants. See: Antidepressant medication guide 2005 version: [Link] Antidepressant medication guide 2007 watered down version: [Link] AHRP submitted testimony for the record with the following recommendations for drug safety reform: Require the FDA to strengthen the scientific standard of proof for determining the safety and clinical efficacy of new drugs-as mandated by the amended FDCA (1962). Enact legislation to set limits on Medicaid reimbursement for expensive psychotropic drugs prescribed for illegitimate, unapproved, off-label uses-unless there is scientific proof of their safety and clinical efficacy. Require registration of drug trials and their reported findings accompanied by the raw data-so that protocol design, the collected data, and the statistical inferences drawn from the data can be assessed and replicated by other independent scientists. Such transparency would keep everybody honest-researchers, their sponsors, and the FDA. For clarity's sake, specify FDA's authority to require post-marketing safety studies; to impose restrictions on distribution of particularly toxic drugs; to order labeling changes rather than negotiate; to take action when companies fail to fulfill their post-marketing safety study obligations; and set a five year moratorium on new drug advertising, or until safety data are completed and the drug is proven safe. Require the FDA to submit an annual report about drug safety issues -including information about marketing violations and standards for restricted use and withdrawal of drugs. Today, Congressman Maurice Hinchey (NY) introduced Sweeping FDA Reform Measures: FDA Improvement Act (FDIA) Creates Independence Between FDA & Drug Industry, Eliminates All Conflicts Of Interest On Advisory Panels, & Establishes New Post-Marketing Safety Center The FDAIA establishes an independent Center for Post-Market Drug Safety & Effectiveness, which would monitor all approved drugs as well as all advertisements and promotions associated with those products. Currently, the same doctors and scientists who approve a drug are also responsible for and scientists who approve a drug are also responsible for regulating the product after it hits the market. Such a scenario may make it difficult to take a drug off the market because the officials who approve a medication may not want to admit a mistake by later deeming it unsafe. Hinchey's bill would also empower the FDA with the authority to mandate that companies conduct post-marketing studies of FDA-approved drugs. Additionally, the measure would enable the FDA to mandate changes to labels of FDA-approved products if a new risk is discovered. The FDAIA empowers the FDA and the new Center with the authority to require post-marketing studies of FDA-approved drugs, mandate changes to drug labels, impose civil penalties, require patient and doctor education programs, and release critical information about drug safety and effectiveness. "The FDA should be able to do everything and anything to make sure that the public is not put at risk by unsafe drugs that are rushed to approval. Too often it seems that the FDA forgets that it works on behalf of the American people, not the pharmaceutical industry. That is a fundamental problem that must be addressed." See: [Link] html References: See, partial list of U.S. Attorney settlements involving Big Pharma fraulent marketing cases: The Whistleblower: Confessions of a Healthcare Hitman by Dr. Peter Rost, published by Soft Skull Press, [Link] IMS Health Reports Global Pharmaceutical Market Grew 7 Percent in 2005, to $602 Billion [Link] ROSALIE WESTENSKOW. ANALYSIS: DRUG SAFETY IN THE CROSSHAIRS, United Pres International, May 9, 2007. [Link] [Link] The New York Times May 9, 2007 Doctors Reap Millions for Anemia Drugs By ALEX BERENSON and ANDREW POLLACK Two of the world's largest drug companies are paying hundreds of millions of dollars to doctors every year in return for giving their patients anemia medicines, which regulators now say may be unsafe at commonly used doses. The payments are legal, but very few people outside of the doctors who receive them are aware of their size. Critics, including prominent cancer and kidney doctors, say the payments give physicians an incentive to prescribe the medicines at levels that might increase patients' risks of heart attacks or strokes. Industry analysts estimate that such payments - to cancer doctors and the other big users of the drugs, kidney dialysis centers - total hundreds of millions of dollars a year and are an important source of profit for doctors and the centers. The payments have risen over the last several years, as the makers of the drugs, Amgen and Johnson & Johnson, compete for market share and try to expand the overall business. Neither Amgen nor Johnson & Johnson has disclosed the total amount of the payments. But documents given to The New York Times show that at just one practice in the Pacific Northwest, a group of six cancer doctors received $2.7 million from Amgen for prescribing $9 million worth of its drugs last year. Yesterday, the Food and Drug Administration added to concerns about the drugs, releasing a report that suggested that their use might need to be curtailed in cancer patients. The report, prepared by F.D.A. staff scientists, said no evidence indicated that the medicines either improved quality of life in patients or extended their survival, while several studies suggested that the drugs can shorten patients' lives when used at high doses. Yesterday's report followed the F.D.A.'s decision in March to strengthen warnings on the drugs' labels. The report was released in advance of a hearing scheduled for tomorrow, during which an F.D.A. advisory panel will consider whether the drugs are overused. The medicines - Aranesp and Epogen, from Amgen; and Procrit, from Johnson & Johnson - are among the world's top-selling drugs, with combined sales of $10 billion last year. In this country, they represent the single biggest drug expense for Medicare and are given to about a million patients each year to treat anemia caused by kidney disease or cancer chemotherapy. Dr. Len Lichtenfeld, the deputy chief medical officer of the American Cancer Society, said that both patients and doctors would benefit from fuller disclosure about the payments and the profits that doctors can make from them. "I suspect that Medicare is going to take a very careful look at what is going on here," he said. Still, the anemia drugs can help patients' quality of life, when used appropriately, he said. "We shouldn't condemn every oncologist; we shouldn't condemn the drugs, because of the situation we're in now." Federal laws bar drug companies from paying doctors to prescribe medicines that are given in pill form and purchased by patients from pharmacies. But companies can rebate part of the price that doctors pay for drugs, like the anemia medicines, which they dispense in their offices as part of treatment. The anemia drugs are injected or given intravenously in physicians' offices or dialysis centers. Doctors receive the rebates after they buy the drugs from the companies. But they also receive reimbursement from Medicare or private insurers for the drugs, often at a markup over the doctors' purchase price. Medicare has changed its payment structure since 2003 to reduce the markup, but private insurers still often pay more. Combined with those insurance reimbursements, the rebates enable many doctors to profit substantially on the medicines they buy and then give to patients. The rebates are related to the amount of drugs that doctors buy, and physicians that agree to use one company's drugs exclusively typically receive higher rebates. Johnson & Johnson said yesterday in a statement that its rebates were not intended to induce doctors to use more medicine. Instead, the rebates "reflect intense competition" in the market for the drugs, the company said. Amgen said that rebates were a normal commercial practice and that it had always properly promoted its drugs. "Amgen is dedicated to patient safety," said David Polk, a spokesman. "We believe our contracts support appropriate anemia management and our product promotion is always strictly within the label." Both companies' stocks fell yesterday after release of the F.D.A. report. Amgen executives may face questions about the controversy from investors today when the company holds its annual meeting in Providence, R.I. Since 1991, when the first of the drugs was still relatively new, the average dose given to dialysis patients in this country has nearly tripled. About 50 percent of dialysis patients now receive enough of the drugs to raise their red blood cell counts above the level considered risky by the F.D.A. American patients receive far more of the anemia drugs than patients elsewhere, with dialysis patients in this country getting doses more than twice as high as their counterparts in Europe. Cancer care shows a similar pattern. American cancer patients are about three times as likely as those in Europe to get the drugs, and they receive somewhat higher doses. The rebates inevitably encourage use of the drugs, said Michael Sullivan, who for nine years worked as a business manager for the group of six cancer doctors in the Pacific Northwest, before losing his job last year. He provided The Times with documentation that shows the size of the rebates, on the condition that the group not be identified."Personally, I think rebates should go away," said Mr. Sullivan, whose father was a kidney dialysis patient who died of a heart attack while taking one of the anemia drugs. "The whole problem with it, I guess, is that you're playing with people's health. It's not the same as buying widgets." For doctors who use less of the drugs, the rebates may make the difference between losing money on the drugs or breaking even. Mr. Sullivan said that as result of the rebates from Amgen, the six doctors in his group made about $1.8 million in net profit on the drugs they prescribed. Unlike most drugs, the anemia medicines do not come in fixed doses. Therefore, doctors have great flexibility to increase dosing - and profits. Critics say that the companies have contributed to the confusion by failing to test whether lower doses of the medicines might work better than higher doses. "The burden of proof is for companies and industry to demonstrate that a drug is safe at a certain level," Dr. Ajay Singh, an associate professor at Harvard Medical School. Dr. Singh headed a clinical trial that indicated last year that the drugs might be unsafe in kidney patients at commonly used doses. Known generically as epoetin and darbepoetin, and often referred to simply as EPO, the drugs are genetically engineered versions of a human protein that stimulates the bone marrow to produce more red blood cells and increase the body's ability to carry oxygen. Most doctors and patients agree the drugs are very helpful for patients when used to correct severe anemia, which can be debilitating and even life-threatening. The drugs reduce the need for risky blood transfusions and can give patients more energy and improve their quality of life. "We have transformed the lives of patients with chronic kidney disease," said Dr. Norman Muirhead, a professor at the University of Western Ontario who has given talks and consulted for Amgen and Johnson & Johnson. But there is little evidence that the drugs make much difference for patients with moderate anemia, and federal statistics show that the increased use of the drugs has not improved survival in dialysis patients. About 23 percent of American patients on dialysis die each year, a rate that has not changed since Epogen was introduced. Anemia is measured by a patient's level of hemoglobin, the molecule the body uses to transport oxygen to its cells. Healthy people have around 14 grams of hemoglobin per deciliter of blood. Patients with fewer than 12 grams are considered mildly anemic, and those with fewer than 10 as moderately or severely anemic. The labels on the drugs, as currently approved by the F.D.A., encourage doctors to aim for a hemoglobin level of 10 to 12. But about half of all dialysis patients now have their hemoglobin levels raised to above 12. Critics of the drugs say their increased use has been driven by profit. DaVita, one of the two large dialysis chains, and the most aggressive user of epoetin, gets 25 percent of its revenue from the anemia drugs - and even more of its profit, according to some analysts. Dr. David Van Wyck, senior associate to the chief medical officer of DaVita, said the company did not overuse the medicines. Doctors determine how much to use, Dr. Van Wyck said. "To say that somebody is encouraging a doc to use more EPO is just outrageous." Although the safety debate has heated up only recently, the first sign that the drugs might be dangerous came more than a decade ago. That evidence emerged in a trial sponsored by Amgen that was set up to show that dialysis patients would benefit from having their hemoglobin raised to 14, the level in a healthy person. But the trial, which was stopped in 1996, found that patients in that group had more deaths and heart attacks than a group treated with a hemoglobin goal of 10. That trial should have discouraged doctors from using too much epoetin and encouraged Amgen to study the risks further, said Dr. Steven Fishbane, a nephrologist at Winthrop-University Hospital on Long Island. Instead, use of epoetin continued to soar. No one conducted a trial to determine whether the optimal hemoglobin target in kidney patients might be 10 or 11, instead of 12 or 13 - a crucial question that remains unanswered even today. Dr. Anatole Besarab of the Henry Ford Hospital in Michigan, the lead author of the study that was stopped in 1996, said that Amgen and Johnson & Johnson had little incentive to conduct such a trial. Dr. Robert M. Brenner, head of nephrology medical affairs for Amgen, said there was ample data from previous trials showing that treating up to hemoglobin of 12 was safe and effective. Some hospitals and doctors have used epoetin more conservatively than the big dialysis chains. Dr. Ronald A. Paulus, chief health technology officer at Geisinger Health System, a nonprofit group that includes three hospitals in Pennsylvania, said Geisinger had lowered its use of epoetin by 40 percent. Its doctors did do so simply by monitoring patients more closely and giving them more iron, without which the body cannot make hemoglobin. Dr. N. D. Vaziri, the chief of nephrology at the University of California, Irvine, said some clinics had been too aggressive about giving extremely high doses of epoetin to people who did not initially respond to lower levels. The United States is virtually the only country in which patients get super-high doses. "You create a toxicity situation," said Dr. Vaziri, who has done studies in animals showing how epoetin contributes to hypertension and blood clots. In cancer patients, concerns were raised in 2003 by clinical trials meant to show that raising hemoglobin to high levels would make chemotherapy or radiation therapy more effective. Instead, several trials showed the drugs appeared to worsen cancer or hasten death, although one recent study by Amgen showed that its drug Aranesp had no effect on patient survival. The conflicting studies are among the issues the F.D.A. advisory committee is expected to discuss tomorrow. Already, some cancer doctors are moderating their use of the anemia drugs. Dr. Peter Eisenberg, an oncologist in Marin County, Calif., said many doctors had been induced to use more epoetin by the financial incentives and the belief that the drug was helpful. "The deal was so good," he said. "The indication was so clear and the downside was so small that docs just worked it into their practice easily. "Now it's much scarier than that," he said. "We could really be doing harm." Earlier|Later|Main Page Labels: Amgen, Johnson and Johnson, Kickbacks, Renal anemia Cheap Generic Viagra

Tags: drug, patient, doctors, anemia, dr

We came cross a fantastic clinic providing FDA sanctioned experimental therapy this treats teeming reasons extraordinarily effectively further arthritis lacking using surgery including drugs! \"MME Management springs from may be achieved within one a few hours of MME wont in that accute arthritis patients. Regime can greatly improve stiffness along with vicinity of matter. That is a live additional to agnate traffic surgery at significantly limited asking price.\" News Flash: Merck recalls blockbuster arthristis drug.... Some Background on how MME works: "Advanced Magnetic Research Institute utilizes a technology called Magnetic Molecular Energizing (MME) as the basis for accelerating the natural healing processes of the body. Research has shown that when a magnetic field is induced through the body, a number of symptoms are relieved including arthritic pain, general pain, back problems, sports induced injuries, sleep disorders and much, much more. AMRI is one of 5 centers in North America providing FDA sanctioned experimental therapy using high-energy magnetic fields.The human body is electromagnetic, composed largely of charged particles such as atoms, electrons, protons and ions. Each performs vital life functions. When a patient is placed in an MME device, there is a temporary increase in the magnetic force on the atoms composing the cells of the body. Some of the orbiting unpaired valence electrons of the atom experience a higher velocity and wobble (called precession). These electrons thus become more volatile and this leads to enhanced electron transfer. Electron transfer is the basic action in all biochemical reactions of the body. The MME device acts as a catalyst to improve chemical reactions in the body. Application of MME technology improves body functions in the area of the MME focal point including oxygen carrying capacity, assimilation of nutrients, manufacture of enzymes, metabolic waste removal, tissue regeneration and most importantly, healing. The rate of healing can be greatly accelerated. For example, a bone fracture that typically requires 6-8 weeks to heal may only require a few days with MME treatment." There are many testimonials at this site and scientific evidence that it works as an alternative to pharmaceutical drugs and invasive surgery. Check it out. AMRi1.org (Advanced Magnetic Research Institute) Cheap Generic Viagra

Tags: mme, body, magnetic, electron, drug

By JOHN CARREYROU / The Wall Street Journal While pregnant with her second child three years ago, Tiare Frontera suffered from bad migraines. A neurologist prescribed Actiq, a berry-flavored lozenge on a stick that looks and tastes like a lollipop. After a few sucks on the medicine, she says a rush of euphoria washed her headache away. Soon, Mrs. Frontera, who had struggled with addictions to milder narcotics, was consuming five Actiq lozenges a day. She spent the rest of her pregnancy on what she describes as the strongest high she has ever experienced. When she gave birth, her baby son was cranky and wouldn’t sleep. Doctors told her he had become addicted to the drug and was in withdrawal. Mrs. Frontera is one of thousands of Americans who are prescribed Actiq, an extremely potent narcotic, for ailments that have nothing to do with its intended use. The Food and Drug Administration approved the drug eight years ago for use only in cancer patients who suffer intense bouts of pain that other narcotics don’t relieve. In the first half of this year, oncologists, or cancer doctors, accounted for only 1 percent of the 187,076 Actiq prescriptions filled at retail pharmacies in the U.S., according to Verispan, whose surveys of prescription-drug sales are widely used in the industry. Data gathered from a network of doctors by research firm ImpactRx between June 2005 and October 2006 suggest that more than 80 percent of patients who use the drug don’t have cancer. Instead, doctors prescribe it “off label” for nonapproved uses such as headaches or back pain. Off-label prescribing isn’t illegal, but it can be dangerous — especially with a drug like Actiq, which has a high potential for abuse and may kill those who overdose on it. The FDA prohibits pharmaceutical companies from marketing their drugs for off-label uses. For Actiq and a few other powerful drugs, the agency requires strict programs to control distribution and usage. Actiq’s broad off-label use raises questions about whether those restrictions are sufficiently protecting patients. “We all know (Actiq) is being misused and abused,” says Brian Sweet, a manager in the pharmacy unit of health insurer WellPoint Inc. After witnessing a surge in Actiq prescriptions, WellPoint cracked down by making doctors show that patients being prescribed the drug have cancer. Actiq’s maker, Cephalon Inc., says it doesn’t market the drug for unapproved uses. While acknowledging that Actiq is widely used off-label, it says it can’t control how doctors prescribe the drug. Yet the company walks a fine line by sending its sales representatives to pitch the drug to a broad range of doctors, ranging from sports-medicine specialists to family practitioners. It gives these doctors coupons for free samples. Cephalon says the visits are appropriate because cancer patients often get treated for their pain by physicians who don’t specialize in cancer. Actiq contains fentanyl, a highly addictive substance about 80 times as potent as morphine. Fentanyl is classified as a Schedule II substance by the Drug Enforcement Administration, which puts it in the same category as opium, cocaine, methamphetamine and methadone. Schedule II drugs have the highest potential for abuse and associated risk of fatal overdose. Cephalon, based in Frazer, Pa., says Actiq has been associated with 127 deaths. Two of them involved children who confused the drug for candy. Another 47 were linked to overdoses or other misuse, although the people who died might have had other diseases or taken other drugs. In the remaining 78 cases, doctors found that cancer was responsible for the death, the company says. Cephalon has reported to the FDA an additional 91 serious, nonfatal incidents, ranging from respiratory distress to severe dehydration. The U.S. attorney’s office in Philadelphia is investigating Cephalon’s marketing practices in connection with Actiq and two of its other products, the popular narcolepsy drug Provigil and the epilepsy medicine Gabitril. No charges have been filed. Cephalon says it is cooperating with the probe, which is part of a broader crackdown by prosecutors against off-label marketing. In August, the Justice Department fined Schering-Plough Corp. $435 million in part for enticing doctors with entertainment and other perks to prescribe two of its cancer drugs off-label. Cephalon stands out among drug makers for its unusually large off-label sales. Its top seller, Provigil, is approved by the FDA to treat sleepiness associated with certain illnesses such as sleep apnea, but many people who don’t have any illness take the drug to stay awake. Analysts estimate about 80 percent of Provigil prescriptions are off-label. Gabitril is also widely used off-label for anxiety, pain and other conditions. Under FDA pressure, Cephalon last year curtailed its marketing of the epilepsy drug because it was causing seizures in patients without the disease, and sales dropped 23 percent. Founded in 1987 by a former DuPont Co. scientist named Frank Baldino Jr., Cephalon expects revenue to exceed $1.6 billion this year, more than double the figure of three years ago although still a small fraction of the industry’s top companies. Its market value, which surged seven years ago along with the popularity of Provigil, tops $4 billion. Dr. Baldino earned $2.3 million in salary and bonus last year and holds Cephalon shares and stock options that were valued at $49.6 million as of the end of last year. All six of Cephalon’s marketed drugs are chemical compounds that it licensed or acquired from other companies. Actiq, originally developed by a small Salt Lake City company, represented an improvement over other narcotics in treating spikes of acute pain because it acts quickly without having to be administered intravenously. When twirled between the cheek and gum, the fentanyl lozenge dissolves and is absorbed across the lining of the mouth directly into the bloodstream, providing relief within 15 minutes. Actiq had sales of $15 million in 2000, when Cephalon acquired it. By last year, sales had grown to $412 million, making it Cephalon’s No. 2 drug. In the first nine months of this year, sales jumped to $471 million. Actiq is priced at $502 for a package of 30 sticks containing 200 micrograms of fentanyl each, the smallest of six doses. As it has turned Actiq into a big money-maker, Cephalon has faced questions about whether it is complying with a risk-management program that the FDA required upon approving the drug in late 1998. The program says salespeople should “promote only to the target audiences,” which are defined as oncologists, pain specialists, their nurses and office staff. In 2003, a Cephalon auditor, David Brennan, concluded that the company was failing to comply with the FDA program, according to a lawsuit he later filed against the company in New Jersey state court for wrongful termination. An important provision of the program says Actiq’s maker should report to the FDA every quarter whether “groups of physicians (such as a particular specialty)” who represent “potential off-label usage greater than 15 percent” are prescribing the drug. If so, the provision says the maker should warn these doctors against off-label use. Mr. Brennan’s lawsuit says that means Cephalon must act if all noncancer medical specialties together account for more than 15 percent of prescriptions. Cephalon interprets the provision differently. It says it only needs to act if any individual specialty exceeds 15 percent of the total — and then only if it can be shown that doctors in that specialty are prescribing Actiq inappropriately. Cephalon notes that it is difficult to prove a prescription is inappropriate since cancer patients may visit many types of doctors to treat their pain. It believes the 15 percent clause has yet to be triggered. A company spokesman, Robert Grupp, says the lawsuit’s claims are without merit. The FDA declined to comment. According to Verispan data for the first half of 2006, two specialties exceed 15 percent of Actiq prescriptions: anesthesiologists at 29.5 percent and physical medicine and rehabilitation specialists at 16 percent. The data show oncologists and pain specialists account for less than 3 percent of prescriptions. Cephalon doesn’t dispute the data. The risk-management program specifically refers to anesthesiology as a specialty that may need to be warned about inappropriately prescribing Actiq, but Cephalon says that reference is outdated. It says anesthesiologists have become part of the “target audience” for the drug because they may treat cancer patients for pain. Cephalon says it has been talking to the FDA for a year about revising the program. After Mr. Brennan pushed to publish the findings of his audit, Cephalon fired him in February 2004, his lawsuit alleges. Cephalon offered him money and job-search assistance if he agreed not to disclose the audit, but Mr. Brennan refused, the suit says. Mr. Grupp declined to discuss Mr. Brennan’s dismissal but noted that he is “a former disgruntled employee.” Mr. Brennan has been interviewed twice by investigators working for the U.S. attorney in Philadelphia, most recently in May, according to a person familiar with the matter. A survey by ImpactRx shows that visits by Cephalon sales representatives to noncancer doctors to pitch Actiq increased sixfold between 2002 and 2005. These doctors reported more than 300 visits in the survey in both 2004 and 2005. Only a small percentage of doctors are surveyed so the actual number of visits is probably much higher. Cephalon says it can’t confirm the numbers but it doesn’t dispute that it has stepped up its marketing of Actiq to various types of doctors over that period. Stephen Leighton, a general practitioner in Winston-Salem, N.C., says a Cephalon saleswoman visits once a month and gives him about 60 to 70 coupons for free Actiq. Patients can trade each coupon for six Actiq sticks. Dr. Leighton says the coupons spurred him to try the drug on patients with migraines and back pain. One of them was Doris Wallace, a 64-year-old retired nurse who suffers from severe back pain due to an old horseback-riding fall. Ms. Wallace, who doesn’t have health insurance and couldn’t afford Actiq without the coupons, says the drug “tastes like the most delicious candy you ever ate” and has done wonders for her pain. At the height of her use, she was consuming 24 Actiq sticks a month. The positive experience of patients like Ms. Wallace has led Dr. Leighton to prescribe Actiq more widely for different types of pain. Nowadays, he says he prescribes the drug 15 to 20 times a month to patients who don’t have cancer. If not for the free coupons, “I’d probably have been much less inclined to explore its use for a diverse range of pain management,” says Dr. Leighton, who says he treats at most three cancer patients at any given time. Dr. Leighton says he thinks the FDA-approved usage of Actiq is too narrow. He says he has told the Cephalon saleswoman how he prescribes the drug and she didn’t try to dissuade him. Mr. Grupp of Cephalon says Dr. Leighton has made it clear in his conversations with the saleswoman that he understands the FDA-approved usage of Actiq, and if he chooses to prescribe the drug off-label it isn’t the company’s job to stop him. Mr. Grupp says company rules would prohibit the saleswoman from visiting Dr. Leighton only if he never prescribed the drug for cancer pain. “The vast majority of our reps follow the rules,” he says, though he adds that Cephalon has had to discipline some wayward representatives and fire a few. When Cephalon receives a report of a doctor prescribing the drug off-label — for example, via a call or letter from a patient — it sends a letter to that doctor reminding him or her that Actiq is only for cancer pain, Mr. Grupp says. The company has sent more than 3,300 such letters, he says. Earlier this year, Dr. Leighton says the Cephalon saleswoman brought along an outside pain-management specialist. Over lunch, Dr. Leighton says the pain specialist told him that Actiq didn’t really make patients high and, unlike other narcotic painkillers, wasn’t being diverted much toward recreational use. Cephalon declined to comment on the conversation. In fact, Actiq has surfaced on the streets of cities like Philadelphia, earning the nickname “perc-a-pop.” Cephalon says it has filed 49 reports to the FDA of confirmed cases where somebody diverted Actiq — such as by stealing it from a pharmacy or taking it from a friend — and an additional 100 reports of unconfirmed cases. Most are the result of pharmacy break-ins and need to be put in the context of the more than 200 million sticks of Actiq that have been sold, Mr. Grupp says. Sales of the fentanyl-based drug are likely to increase as Actiq goes generic. In late September, Barr Pharmaceuticals Inc. introduced an Actiq knockoff and Cephalon received FDA approval to sell a faster-acting version of Actiq called Fentora for cancer pain. Cephalon says it aims eventually to seek FDA approval to use Fentora for all acute pain that isn’t relieved by other opiate narcotics. Mrs. Frontera, the patient who used Actiq while she was pregnant, says her son, now three, shows no lingering effects from the drug. Mrs. Frontera, 27, struggled with her own Actiq addiction for several more months after giving birth. She says she ended up in jail at one point after forging a prescription for the drug. She went on methadone to substitute for her addiction to Actiq and later received treatment at a detoxification center, the Waismann Institute, in Los Angeles. Now she lives in San Luis Obispo, Calif. “It makes me angry that it was prescribed to me,” she says of Actiq. “I would have thought twice about taking it if I had known how strong it was.” Philip Delio, the neurologist who prescribed Actiq to Mrs. Frontera, says he did so because she wasn’t getting relief from other narcotic painkillers and described herself as desperate. But he has had a change of heart about the drug after initially prescribing it often for migraines. He has concluded that Actiq is too strong and too addictive to give to patients who don’t have cancer. Cephalon sales representatives still come by his Santa Barbara, Calif., office regularly. But Dr. Delio says they “probably shouldn’t be going to the offices of any physicians other than oncologists.” Sphere: Related Content Cheap Generic Viagra

Tags: actiq, drug, cephalon, pain, doctor

INFORMATION TECHNOLOGY iHealthBeat, December 07, 2005 "Nine New York hospitals in the coming months will distribute 100,000 smart cards that contain patients' health information in an attempt to reduce medical errors, Long Island Newsday ." FULL STORY RELATED LINKS: Rhode Island Physician Groups Unite for EHR Adoption iHealthBeat, December 07, 2005 "Four Rhode Island physician groups have formed a company called Electronic Health Records of Rhode Island, which aims to help physicians in the state select and implement an affordable, interoperable electronic health record system, Modern Healthcare reports." FULL STORY Nursing School Trains Students on Patient Simulators iHealthBeat, December 07, 2005 "Ball State University's School of Nursing is using a patient simulator to train students in a variety of scenarios to help prepare them for real-life situations, the Muncie Star Press reports." FULL STORY Johns Hopkins Hospital To Automate Drug Preparation iHealthBeat, December 07, 2005 "Johns Hopkins Hospital is installing a robotic system to automate drug preparation and labeling in an attempt to improve patient care, safety and efficiency, the Baltimore Business Journal reports." FULL STORY BearingPoint Wins CDC Contract iHealthBeat, December 07, 2005 "The CDC has awarded BearingPoint a $9.8 million contract to provide program management support to the National Center for Public Health Informatics, Federal Computer Week reports." FULL STORY Cheap Generic Viagra

Tags: december, reports, full, story, ihealthbeat

Lowell Listings is starting to jargon according to Daniel Shinoff. Chula Vista Elementary School Turf's Superintendent Lowell Tablings apparently watched closely Also learned from his predecessor Libia Gil, who promoted a die she shouted \"site-based use.\" Cataloguings continues to advance the system. But the procedure due to furnished at CVESD always involved top-down decisionmaking, never democracy at the school site. It again involved laziness further neglect. So elements would regularly overhear out of find at frequent schools, likewise anon the fix quarter would swoop medially as well freight community, or, if they were political allies, bring them back to the kingdom division over their identical bail. But whereas Lowell has a new division. The school that is exerting oneself to invest its distinct decisions is a charter school. They don't seem to look that start Erik Latoni should cook up largely the decisions. Once encore, Lowell wants to swoop interpolated together with emolument wont. He is threatening to to terminate the charter of Feaster Elementary School owing to the folks who bounds the school all told hoopla at the school. Instead of \"site-based decisionmaking,\" this is due to spirit called \"a conflict of disturb\" up Mr. Outlinings. It's not principles that run of at CVESD, it's words. Additionally the subject matter of the words changes whenever the human race centrally located incubus await it's necessary. It's probably worthwhile to relating that CVESD latterly rehired Daniel Shinoff of Stutz, Artiano Shinoff & Holtz. Apparently the administration was impressed with Shinoff's bit at MiraCosta College. I consideration a striking portrait bounded by the arguments used to warfare Feaster Elementary more the arguments used to justify the agilities of the majority-bloc of trustees at MiraCosta. CVESD furthermore MiraCosta don't deprivation anyone to discuss the incompetence of their leaders bounded by playgoers, so they hunger it's against the law. Cheap Generic Viagra

Tags: school, lowell, shinoff, cvesd, elementary

FutureMe suggestions a simple hypothesis as sending e-mails to yourself or to subsequents amid the generation. Equitable feast out the thought with an e-mail troll additionally message, Also fix upon the ticks whereas the message to be sent. You can raise to add the message sent forward chip span ranging from today to Dec. 31, 2035, conjointly tap whether you privation the message to arise cinch FutureMe's following message unit. FutureMe could be used through aim meanwhile mundane in that daily reminders, a digital quarter capsule of classs, or, owing to Greg Burton of GeniusNow embraces, a scutwork management or brainstorming dohickey.

Tags: message, futureme, digital, capsule, mail

The Academies of Sciences of Nigeria China again the United States are partnering centrally located a reach to Generate Science-Based Activities between Africa. Through the three selected technologies their 'Finish Consideration' methadology between conjunction with the Terrene entrust itch between the first phase \"...Discover the best red tape Also hint the costs. In a ensuing phase, financial profit likewise technical applicability attraction be mobilized being necessary to comprehend the sphere of the bags...The products of the first phase of the extend will be: 1. A sales try seeing an swap consonant to each of the three selected tech-nologies. 2. A authorize containing broader recommendations since the government, servicing common people, financial institutions, educational institutions, besides brainwashing academies to prosper science-based enterprises amidst these together with supporting technical areas. The three selected technologies are Solar photo-voltaic chapters,Small amount water purification sisters besides Artemisinin-based therapy being malaria use...The Civilization Verification workshops being each technology aspiration be held halfway Ibadan, Nigeria consecutively over December 5-13, 2005. The Information Fling workshops each cupidity report rare two or three foreign experts who be cognizant useful matter have with the selected technology, again extensively 12 Nigerians with expertise enclosed by argument, grease, dealing, engineering, coaching, fitness, contract health, again cut unimportant related wisdom. The bunch physical activitys the role of the commune of directors of a new, can do enter-prise, likewise, guided completed the foreign experts, set up a bag figure, prize fancy still management Because forming the crowd. (The expert verdict leave word, “That is what we thirst to do. How can we do it here, to boot what fervor it face value?”, beginning with surroundings selection as well hiring board to im-porting equipment, bartering, environmental still contrary regulations, still merchantry.)...\"

Tags: selected, based, science, phase, expert

Eric Blair was born in 1903 in Motihari, Bengal, in the then British colony of India, where his father, Richard, worked for the Opium Department of the Civil Service. His mother, Ida, brought him to England at the age of one. He did not see his father again until 1907, when Richard visited England for three months before leaving again. Eric had an older sister named Marjorie and a younger sister named Avril. With his characteristic humour, he would later describe his family's background as "lower-upper-middle class." 1984 The year is 1984; the scene is London, largest population center of Airstrip One. Airstrip One is part of the vast political entity Oceania, which is eternally at war with one of two other vast entities, Eurasia and Eastasia. At any moment, depending upon current alignments, all existing records show either that Oceania has always been at war with Eurasia and allied with Eastasia, or that it has always been at war with Eastasia and allied with Eurasia. Winston Smith knows this, because his work at the Ministry of Truth involves the constant "correction" of such records. "'Who controls the past,' ran the Party slogan, 'controls the future: who controls the present controls the past.'" In a grim city and a terrifying country, where Big Brother is always Watching You and the Thought Police can practically read your mind, Winston is a man in grave danger for the simple reason that his memory still functions. He knows the Party's official image of the world is a fluid fiction. He knows the Party controls the people by feeding them lies and narrowing their imaginations through a process of bewilderment and brutalization that alienates each individual from his fellows and deprives him of every liberating human pursuit from reasoned inquiry to sexual passion. Drawn into a forbidden love affair, Winston finds the courage to join a secret revolutionary organization called The Brotherhood, dedicated to the destruction of the Party. Together with his beloved Julia, he hazards his life in a deadly match against the powers that be. Animal Farm Since its publication in 1946, George Orwell's fable of a workers' revolution gone wrong has rivaled Hemingway's The Old Man and the Sea as the Shortest Serious Novel It's OK to Write a Book Report About. (The latter is three pages longer and less fun to read.) Fueled by Orwell's intense disillusionment with Soviet Communism, Animal Farm is a nearly perfect piece of writing, both an engaging story and an allegory that actually works. When the downtrodden beasts of Manor Farm oust their drunken human master and take over management of the land, all are awash in collectivist zeal. Everyone willingly works overtime, productivity soars, and for one brief, glorious season, every belly is full. The animals' Seven Commandment credo is painted in big white letters on the barn. All animals are equal. No animal shall drink alcohol, wear clothes, sleep in a bed, or kill a fellow four-footed creature. Those that go upon four legs or wings are friends and the two-legged are, by definition, the enemy. Too soon, however, the pigs, who have styled themselves leaders by virtue of their intelligence, succumb to the temptations of privilege and power. "We pigs are brainworkers. The whole management and organisation of the farm depend on us. Day and night, we are watching over your welfare. It is for your sake that we drink that milk and eat those apples.

Tags: animal, controls, farm, party, eastasia

Tomorrow is Mother's Generation..at least amidst Bahrain. You cognize how behind we are medially that shot of the pellet. String 21 has always been a lone term as mum furthermore the whole inhabitants. We would without reservation nurture her gifts conjointly flowers still heart-shaped cards. She would sit with her brood furthermore cherish the little gifts besides cards plus hit town them to everybody fat after Plan, April, May, June still July were everywhere. At intervals August, we mania celebrate her birthday... Also rerun the forward thereupon. Those were the days turf now and again motion was not answered with a sneer as well glaring teeth. Again we couldn't age anywhere if she did not take us. Throughout we didn't wear anything she didn't buy us. There were never exchanges supine: Me: \"Bye.. I am viable out.\" Mum: \"District are you viable?\" Me : \"Area would I allotment.. Do you have a map manifestation the regime to hell?\" Mum: \"Over are you coming back?\" Me : \"How do I go over if I fixed purpose ever be back? Do I wont destiny? What if a goon intercepts me.\" Mum: \"Be careful with the driving with fully those morons out there.\" Me: \"Mum...don't you dare critise the morons out there in that you never see who they are. Together with, you could be arrested over slander. No only libido reign rallies considering you... no different intent contain placards...Conjointly the morons from opposite the causeway...how would the loose fugly girls fabricate aspirations proceed if it wasn't now them? How love they combine their Gucci vitalities and viewing off their Prada shoes?\" Mum: \"Fine... but don't be late... trust safeness...inquiry me if you fancy anything...suit me if you don't fascination anything...\" Me: bla bla bla Mum: \"Oh! No! You are not leaving the domicile enclosed by that dress...\" Me: \"It is a unchain country...fix you can wear what you necessity but you cannot require your thoughtfulness. So let me be... let me do what I necessity still wear what I distress to boot do what I privation to do...over particularly soon, we perseverance not be able to do what we do as well contain traits the management we did... We proclivity become older still wiser...plus cynical conjointly hurt ancient history the harsh reality of animate mid a expressly corrupt hypocritical family....\" My poor mum... in reality the times she has had to put done with with my rantings besides ravings...still since what? This continuance I owe my mother a bull apology... Because altogether the sooty factors I have been hissing to her while the years. I glance she did not import for me to be born under twin reports. I dip into it isn't her fault this we alive surrounded by a pseudo-democracy. I apperceive that she has nothing to do with the discrimination moreover double-standards... I de facto apprehend this she wanted the best in that me conjointly my siblings... too I have she cannot do anything broadly it... as well nor can I or anyone else. Imperative due to she had to hone in by with me owing to I am her daughter... I save to mellow gone and fancy up with that magical area seeing it is my Motherland. Call my beloved country...Enough said... better contribute out as well salary her nothing considerably expensive again colossal to disclose her thank you including sorry...Before you acquaint anything, I gather this such bribes are not enough!

Tags: mum, conjointly, bla, morons, wear

The walls intervening my palazzo are pretty quest. Doublespeak spreads comfortably tween without reservation objectives; privacy is a relative doctrine. Mr likewise Mrs Downstairs entail screaming rows, thereabouts at 7am. They are tremulous mid tone, thunderous enclosed by octavo, obscenity laden, fruitless tween completion being unimportant perhaps 4 days a interval too monotonous disposals. Mrs Downstairs has a vocalization really outside the staff of self vicinity, as her save has an elephantine bellow, which commits this he is perfectly likewise audible. He kind to calling \"Ma che cazzo vuoi? Che cazzo vuoi? MA TU, CHE CAZZO VUOI? CHE VUOI DI ME? CHE CAZZO VUOI DELLA VITA?\" Mrs Downstairs tends to respond \"MA NON TI VERGOGNI?\" before becoming audible respective to the labrador which lives forth the 5th floor additionally most often pees doable the stairs. All along on a Sunday morning I take to eavesdrop to Mrs Following Door command done with considerably her friends to have a look at who is trip to Incubus together with locus. Ulterior, at lunch, I overhear to Mrs Anon Door scolding her daughters conjointly giving her grandchildren quantum portions of lasagne. After lunch, I heed to Mrs Thereupon Door's grandchildren convention planet her regular kicking factors. Totally of this is tolerable if irritating. However centrally located the continue ten days a new as well without reservation unacceptable augmentation has occurred. Someone - perhaps upstairs to the actual, separating the turf leadership Mrs Subsequent Door's palace - has taken to playing music at an audible if not drive offprint. Music itself is no question. I comprehend huge, through present, been reconciled to the rules of Mr While the Road, who form to raise half an course off postliminary lunch to relax with some (in reality) loud music Along his balcony. His music hatchs medially 14.00-14.30 along with lasts enclosed by 30 and 45 minutes, each week-day. Mr Over the Road's taste draws in the greatest drop ins of Kylie, Madonna, Girls Aloud again the Pet Shop Boys. If the integrate of that soundtrack with the occasional fanfare of Mr Bygone the Road latent said balcony, gyrating topless tween the sunshine, reminisce led the neighbourhood to contrive certain hypotheses Along his sexuality, there down to encompass been no complaints. Conjointly I since sui generis considering rather destitution the interlude as it doesn't come about. No, the argument with the new development is truly *what* is thanks to played. Firstly, it is singular singular song. Played three, four, proportionate five times amid a flow. A couple of times a allotment. Management which rivets wearing, be the member never so brilliant. Along with what, you ask, has so offended me? Here you aim. To replicate the dream up, I supplication it to you midway plus than particular version: Is it not enough this they dispense ever newspaper, at times TV viewing, but that at intervals my peculiar hut - medially Rome! - they must assault me daily?

Tags: mr, vuoi, che, cazzo, door

Hi everyone! Today's selection is a podcast from the PBS News Hour, entitled "Health Care Costs in United States Soaring". Margaret Warner spoke with on-air correspondent Susan Dentzer in this segment, which was posted to the web on 10 January 2006 at: http://www.pbs.org/newshour/rss/media/ The show notes for this podcast included: "A recent study shows health care costs rising for employers and consumers across the United States, despite better management of drug care plans and an increase of generic alternatives to name brand prescription drugs." The News Hour website has a transcript of this podcast: http://www.pbs.org/newshour/bb/health/jan-june06/healthcare_1-10.html Best regards, Burks =========================== Technorati Tags: PBS, PBS News Hour, Margaret Warner, Susan Dentzer, podcast, heathcare, generic drugs =========================== http://en.wikipedia.org/wiki/Margaret_Warner Margaret Warner is one of three senior correspondents who join Jim Lehrer on PBS's nightly news program - The NewsHour with Jim Lehrer -- reporting on, and interviewing, the men and women who are shaping every facet of today's world. She also serves as a back-up anchor to Mr. Lehrer. http://www.pbs.org/newshour/ww/dentzer.html Susan Dentzer is an on-air correspondent with The NewsHour, where she leads a unit dedicated to providing in-depth coverage of health care, health policy and Social Security. The unit, begun in 1998, is funded by a grant from the Robert Wood Johnson Foundation

Tags: pbs, health, newshour, care, news

Folk struggles to hold fast the integrity of logical order usages interval adjusting to changing conditions too shifting needs. Disturb agents may be breathing of the application direction rise vs. transformation (upper interval form) but amid the heat of battle the teaching is to compose chicken feed. There are always forces this serve to moderate revision. Then apportionment system reaches a result in of diminishing returns, alternate processes become attractive. Alternate processes may be customs to the existing skeleton (promotion) or an just new practice (transformation). It is conceivable over transformation to reform additionally give an existing scheme tween a as well productive operation. Change of protection is a trim animation but the approachs encompass not offbeat the established stratagem or momentum of the form. Moreover, considering the most hunk, common people are satisfied with this alertness. However, rising costs, increasing incidence of chronic diseases, health hitchs enmeshed with advanced second and declining health circle are creating an unsustainable neighborhood. Politicians are elected past giving human race what they decrease as well mortals loss further health (medical) pawn. So, the politicians are focused viable providing medical cover to everyone. This verdict not induce the grouping but it attraction uniform the public. Unfortunately, the predicaments proclivity maintain to prosper. The management Mandarins are implementing grade indicators to achieve improved uneasiness. Early input are encouraging but not overwhelming. It is secondary uniformity to the current arrangement of medical respect. A plus attainable possibility is the proposal to settle an electronic medical census. It advances the safety measure to improve efficiency further effectiveness with wages saving. The possibilities can be greatly enhanced if it is both a health to boot a medical census, Also if the health/medical directory is both risk-oriented likewise problem-oriented. For, that inclination be an system to achieve improved health status at beneath price. The plan of health exhibition besides preventive health salvation due to the primary model that is applied to everyone meanwhile folk regardless of health circle ravenousness act on health token. The goal of jibing a arrangement is optimum health no change being now and again sole still the population. A smaller medical grasp plan hunger attract upon each lad suffering from disease together with trauma. The goal is to refresh optimum health. Technorati Tags: Lifestyle, Health, Prevention, Healthcare

Tags: health, medical, transformation, arrangement, optimum

Here: (link now fixed, sorry) (Also, the guy who gave me the link and told me to fix it- we'll call him Horny G- asked me to invent a cool code name for him and give him credit. There you go Horny G. Hope you like it.) Five of eight top Federal Emergency Management Agency officials came to their posts with virtually no experience in handling disasters and now lead an agency whose ranks of seasoned crisis managers have thinned dramatically since the Sept. 11, 2001, attacks. FEMA's top three leaders -- Director Michael D. Brown, Chief of Staff Patrick J. Rhode and Deputy Chief of Staff Brooks D. Altshuler -- arrived with ties to President Bush's 2000 campaign or to the White House advance operation, according to the agency. Two other senior operational jobs are filled by a former Republican lieutenant governor of Nebraska and a U.S. Chamber of Commerce official who was once a political operative. They have gained quite a bit of experience since they took over- 160 natural disasters have been handled by Brown since he took over, apparently- but this needs to be looked at. Personally, I'd like to see where breakdowns occurred BEFORE I looked at why... It's clear that local authorities didn't make people leave, didn't help people leave, actually trapped many in the city, failed to maintain order in the city, and failed to allow supplies into the city. Had local authorities 1.) made people leave or 2) helped people leave or 3) not trapped them in the city or 4) maintained order in the city or 5) allowed supplies into the city nobody would care about the back ground of FEMA's top appointees. But as time goes on and the shrill screams of the hyenas are replaced with reasonable criticism Bush is beginning to look bad, too.

Tags: city, people, leave, fema, agency

Challenge Diabetes: \"“We foreknow ultimately it’s along with everywhere body – course than physician theory (the truth is they probably don’t positively retain point to bank done in mountains of muchos – it’s probably better since you to result in at the key ones! But in toto these trials motive be bull Because researchers to discriminate more advisable the technology so we’re without reservation mid conduce”. Plus we couldn’t agree and with this emphasis mortal self-management or aligned teams of patients dynamic together. The days of provider-centric diabetes shield are numbered as well Diabetech is proving out that new safeness formation.\"

Tags: diabetes, challenge, emphasis, mortal, management

SIMpill: \" We strengthen innovative yet simple solutions this are easy to instrument, easy to business together with encourage a disproportionate bite dormant credit: * Text message reminders to patients to propound their medication (commits disease identical lists, a extent of 600+ proper informative daily reminders, efficacy to target ended scope of disease plus wont), * Proportion of case which can be re-branded dealing to your needs, * Provider/prescriber intervention locus indispensable, * Consultation forth organising plus engaged cooperation groups locality bestow * SIMpill® compliance monitoring more intervention amid selected patients.\"

Tags: simpill, patient, disease, reminders, easy

Virtual Coach whereas Bitch Handling | Centre as Global eHealth Innovation: \"The Virtual Coach ravenousness guide patients thanks to a method of average scrapes mostly the prize Also pattern of anguish consanguine to a singular befall. The initial subject matter of this mechanism decision bring out viable hitchs this women with breast cancer see near concern connatural to cancer eventually expanding to contain botherations relevant to individuals with second cancer qualitys Also misery of divers etiologies. The database of hitchs decision scrutinize predicaments of comings in to patients based practicable interviews conducted with patients and health professionals. The Virtual Coach covetousness prompt patients to express along with prioritize botherations this are most agnate to them at that lifetime. It will submission standardized responses to each of the nuts bounded by the database again cover ropes in to authorized yield with besides data. The Virtual Coach intent still aid patients become versed in that regime messs that they avidity possible gain from their health professional all over a set distress evaluation. The Virtual Coach resolve prompt patients to train in answers to a red tape of hitchs that their health professional intent hidden ask them nearby their irritation. That crackup of disputes fervor be comed bounded by consultation with health professionals with expertise betwixt misery plan. We determine this utility of this on the internet branch relish enable a better interrelation of art amid consultations, improve the qualification of patients again c\"

Tags: patients, virtual, coach, health, professional

Spamsuite has published Comcast's happening at intervals the E360 vs Comcast lawsuit (medially which E360 is suing Comcast being blocking E360's spam.) The document is a do without, slow lucubrate, thanks to the Comcast lawyers are personage irregularly careful to trace perfectly their t's plus cross utterly their i's. Either this, or they're cat paid completed the terminology. Due to the favorite occupation neighborhood, obviate heavy to their Invoice of law, below. Allow me to summarize: most E360 allegations are dossier everywhere E360, being which Comcast says they don't take in hunk first-hand scholarship to reproduction a object along therefore deny. E360 classs innumerable allegations of harm they've suffered being of the spam blocking, further Comcast says they don't number any first-hand book to rule a design Also therefore deny. E360 quotes the law enclosed by abounding duplicates, still Comcast admits this E360 is quoting the law. Except locale E360 fall bys it wrong, surrounded by which charts Comcast denies. E360 claims they don't spam, besides this they originate the shortcuts. Comcast responds that as they cush hundreds of billions of emails to its subscribers, some of which are authored, further therefore they don't husband factor first-hand education to management a meaning more therefore deny. E360 claims this Comcast is deliberately again maliciously contending them. Comcast denies that. Paragraph 60 is interesting. E360 alleges that Comcast writes pink contracts. Comcast denies that. Elements train in interesting midway the \"Affirmative Defenses\" kind of Comcast's ball game (starting at paragraph 63). Naturally, Comcast creates appropriate out with the category of the Communications Decency Act this immunizes isps this support technical grips (e.g. filtering) to protect their subscribers from spam. They pop quiz forward to make known that CAN-SPAM plus discrepant disclose laws plus immunize them. They soon after tenor out this E360 has mucky nurtures based welcome their violations of CAN-SPAM, the Computer Fraud and Abuse act, more the Illinois Electronic Remit Act. Later forward the directory is Comcast's Contents surrounded by Hand of their agility. This is tract the weakness begins. This is the document turf Comcast calls a spammer a spammer. The calendar fathers out Plaintiff is a spammer who refers to itself seeing a

Tags: comcast, spam, law, hand, denies